邮件订阅 RSS

留言板

尊敬的读者、作者、审稿人, 关于本刊的投稿、审稿、编辑和出版的任何问题, 您可以本页添加留言。我们将尽快给您答复。谢谢您的支持!

姓名
邮箱
手机号码
标题
留言内容
验证码

心力衰竭：预防和治疗缺一不可

徐芬,  周洲

downloadPDF
文章导航 > 协和医学杂志  > 2022 >  13(6): 953-957
徐芬, 周洲. 心力衰竭：预防和治疗缺一不可[J]. 协和医学杂志, 2022, 13(6): 953-957. doi: 10.12290/xhyxzz.2022-0440
引用本文: 徐芬, 周洲. 心力衰竭：预防和治疗缺一不可[J]. 协和医学杂志, 2022, 13(6): 953-957. doi: 10.12290/xhyxzz.2022-0440
shu
XU Fen, ZHOU Zhou. Heart Failure: Prevention and Treatment are Indispensable[J]. Medical Journal of Peking Union Medical College Hospital, 2022, 13(6): 953-957. doi: 10.12290/xhyxzz.2022-0440
Citation: XU Fen, ZHOU Zhou. Heart Failure: Prevention and Treatment are Indispensable[J]. Medical Journal of Peking Union Medical College Hospital, 2022, 13(6): 953-957. doi: 10.12290/xhyxzz.2022-0440
shu

心力衰竭：预防和治疗缺一不可

doi: 10.12290/xhyxzz.2022-0440

  • 国家心血管病中心 中国医学科学院阜外医院实验诊断中心，北京 100037

详细信息
    通讯作者:

    周洲, E-mail: zhouzhou@fuwaihospital.org

  • 中图分类号: R541;R446

Heart Failure: Prevention and Treatment are Indispensable

  • Center of Laboratory Medicine, Fuwai Hospital, Chinese Academy of Medical Sciences & Peking Union Medical College, National Center for Cardiovascular Diseases, Beijing 100037, China

More Information

    摘要
  • 摘要: 美国心脏协会、美国心脏病学会和美国心力衰竭协会联合发布了《2022年AHA/ACC/HFSA心力衰竭管理指南》。该指南倡导心力衰竭防治并重，强调基于利钠肽筛查的一级预防对A期(心力衰竭风险期)或B期(心力衰竭前期)患者至关重要; 推荐C期(心力衰竭期)患者应接受多学科团队管理，尽早使用包括钠-葡萄糖协同转运蛋白2抑制剂的“基础四联疗法”; 并推荐将希望延长生存期的D期(心力衰竭晚期)患者及时转诊至心力衰竭专科团队，以评估晚期心力衰竭治疗的适用性。
    Abstract: Recently, 2022 AHA/ACC/HFSA Guideline for the Management of Heart Failure has been published. It advocates to pay equal attention to the prevention and treatment of heart failure; and emphasizes that primary prevention based on natriuretic peptides screening is essential for patients at risk for heart failure or with pre-heart failure. Furthermore, it recommends that patients with symptomatic heart failure should receive care from a multidisciplinary team to facilitate the implementation of "basic quadruple therapy" including sodium glucose cotransporter 2 inhibitors; and that patients with advanced heart failure who wish to prolong their survival should be timely referral for heart failure specialty care and assess suitability for advanced heart failure therapies.
    作者贡献：徐芬负责撰写论文; 周洲负责审校论文。
    利益冲突：所有作者均声明不存在利益冲突
    • HTML全文
    • 参考文献(16)
  • [1] Heidenreich PA, Bozkurt B, Aguilar D, et al. 2022 AHA/ACC/HFSA Guideline for the Management of Heart Failure: A Report of the American College of Cardiology/American Heart Association Joint Committee on Clinical Practice Guidelines[J]. Circulation, 2022, 145: e895-e1032.
    [2] 《心力衰竭通用定义和分类》将开启心力衰竭诊疗的标准化进程[J]. 协和医学杂志, 2021, 12: 621-623.
    [3] McDonagh TA, Metra M, Adamo M, et al. 2021 ESC Guidelines for the diagnosis and treatment of acute and chronic heart failure[J]. Eur Heart J, 2021, 42: 3599-3726. doi:  10.1093/eurheartj/ehab368
    [4] Faggiano P, Bernardi N, Calvi E, et al. Stage A Heart Failure: Modern Strategies for an Effective Prevention[J]. Heart Fail Clin, 2021, 17: 167-177. doi:  10.1016/j.hfc.2021.01.004
    [5] Redfield MM. Strategies to screen for stage B as a heart failure prevention intervention[J]. Heart Fail Clin, 2012, 8: 285-296. doi:  10.1016/j.hfc.2011.12.001
    [6] Yancy CW, Jessup M, Bozkurt B, et al. 2013 ACCF/AHA guideline for the management of heart failure: a report of the American College of Cardiology Foundation/American Heart Association Task Force on Practice Guidelines[J]. J Am Coll Cardiol, 2013, 62: e147-e239. doi:  10.1016/j.jacc.2013.05.019
    [7] Yancy CW, Jessup M, Bozkurt B, et al. 2017 ACC/AHA/HFSA Focused Update of the 2013 ACCF/AHA Guideline for the Management of Heart Failure: A Report of the American College of Cardiology/American Heart Association Task Force on Clinical Practice Guidelines and the Heart Failure Society of America[J]. Circulation, 2017, 136: e137-e161.
    [8] Arnett DK, Blumenthal RS, Albert MA, et al. 2019 ACC/AHA Guideline on the Primary Prevention of Cardiovascular Disease: A Report of the American College of Cardiology/American Heart Association Task Force on Clinical Practice Guidelines[J]. Circulation, 2019, 140: e596-e646.
    [9] Ledwidge M, Gallagher J, Conlon C, et al. Natriuretic peptide-based screening and collaborative care for heart failure: the STOP-HF randomized trial[J]. JAMA, 2013, 310: 66-74. doi:  10.1001/jama.2013.7588
    [10] Huelsmann M, Neuhold S, Resl M, et al. PONTIAC (NT-proBNP selected prevention of cardiac events in a population of diabetic patients without a history of cardiac disease): a prospective randomized controlled trial[J]. J Am Coll Cardiol, 2013, 62: 1365-1372. doi:  10.1016/j.jacc.2013.05.069
    [11] Suthahar N, Lau ES, Blaha MJ, et al. Sex-Specific Associations of Cardiovascular Risk Factors and Biomarkers with Incident Heart Failure[J]. J Am Coll Cardiol, 2020, 76: 1455-1465. doi:  10.1016/j.jacc.2020.07.044
    [12] Bozkurt B. It Is Time to Screen for Heart Failure: Why and How?[J]. JACC Heart Fail, 2022, 10: 598-600. doi:  10.1016/j.jchf.2022.06.001
    [13] McMurray JJV, Solomon SD, Inzucchi SE, et al. Dapagliflozin in patients with heart failure and reduced ejection fraction[J]. N Engl J Med, 2019, 381: 1995-2008. doi:  10.1056/NEJMoa1911303
    [14] Packer M, Anker SD, Butler J, et al. Cardiovascular and renal outcomes with empagliflozin in heart failure[J]. N Engl J Med, 2020, 383: 1413-1424. doi:  10.1056/NEJMoa2022190
    [15] Zannad F, Ferreira JP, Pocock SJ, et al. SGLT2 inhibitors in patients with heart failure with reduced ejection fraction: a meta-analysis of the EMPEROR-Reduced and DAPA-HF trials[J]. Lancet, 2020, 396: 819-829. doi:  10.1016/S0140-6736(20)31824-9
    [16] Sharma A, Verma S, Bhatt DL, et al. Optimizing Foundational Therapies in Patients With HFrEF: How Do We Translate These Findings Into Clinical Care?[J]. JACC Basic Transl Sci, 2022, 7: 504-517.
    • 相关文章
    • 施引文献
  • 资源附件(0)
  • 加载中
WeChat 点击查看大图
计量
  • 文章访问数:  280
  • HTML全文浏览量:  66
  • PDF下载量:  83
  • 被引次数: 0
出版历程
  • 收稿日期:  2022-08-10
  • 录用日期:  2022-10-16
  • 网络出版日期:  2022-10-17
  • 刊出日期:  2022-11-30

目录

    /

    返回文章
    返回
    友情链接: 国家卫生健康委员会 北京协和医院 中国医学科学院 学术不端检测系统 国际知识资源总库 中国知网 术语在线 中国全科医学
    地址：北京市东城区帅府园1号 北京协和医院老楼7号楼
    3层302室 《协和医学杂志》编辑部
    电话：010-69154261/4262
    E - mail：medj@pumch.cn
    mjpumch@126.com
    期刊网站版权所有：《协和医学杂志》编辑部
    京ICP备 11002662

    本系统由 北京仁和汇智信息技术有限公司 开发    百度统计

    x 关闭 永久关闭

    【温馨提醒】近日，《协和医学杂志》编辑部接到作者反映，有多名不法人员冒充期刊编辑发送见刊通知，鼓动作者添加微信，从而骗取版面费的行为。特提醒您，本刊与作者联系的方式均为邮件通知或电话，稿件进度通知邮箱为：mjpumch@126.com，编辑部电话为：010-69154261，请提高警惕，谨防上当受骗！如有任何疑问，请致电编辑部核实。谢谢！